We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sanofi has signed a licence agreement with Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSK) for non-CAR use of a new human binding domain for the potential treatment of multiple myeloma.
Eli Lilly and MiNA Therapeutics have entered a global research partnership to develop new drug candidates using the latter’s small activating RNA (saRNA) technology platform.
French pharma company Servier has entered into a research partnership with UK biotech MiNA Therapeutics to develop small activating RNA (saRNA) therapies for the treatment of neurological diseases.
UK-based MiNA Therapeutics has entered into a research collaboration agreement with AstraZeneca to assess small activating RNA (saRNA) molecules in metabolic diseases.